basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pediatric Kidney Transplantation
Conditions
Pediatric Kidney Transplantation
Trial Timeline
May 1, 2001 → —
NCT ID
NCT00228020About basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids
basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids is a phase 3 stage product being developed by Novartis for Pediatric Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00228020. Target conditions include Pediatric Kidney Transplantation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00228020 | Phase 3 | Completed |
Competing Products
20 competing products in Pediatric Kidney Transplantation